EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Benjamin Rich iD, Meenakshi Srinivasan iD, Yu Liu Ho iD, Sandra A G Visser iD, Geraldine Ferron-Brady iD, Georgios Vlasakakis iD

Clinical Pharmacology & Therapeutics · 2026-03 · 119 (3) · 629-640

DOI: 10.1002/cpt.70076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 07.10.2025. Verfasst von Benjamin Rich und 5 weiteren Autor:innen. Beteiligte Einrichtung: InnoMx, Outremont, Quebec, Canada. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrimidines, Benzamides, Pyrrolidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III trials and other participants from phase I trials ( N = 661). Predicted covariate effects on momelotinib, M21, and total active moiety (TAM)—representing the combined potency‐weighted exposures of momelotinib and M21—exposures following 200‐mg once‐daily dosing were evaluated using a simulation‐based approach. Using sequential modeling, momelotinib was described by a two‐compartment model with six transit absorption compartments and first‐order elimination, and M21 by a two‐compartment model with first‐order elimination. Hepatic function, concomitant CYP3A4 inducers, and concomitant OATP1B1/1B3 inhibitors were significant momelotinib covariates, while baseline creatinine clearance and hepatic function were significant M21 covariates, with cumulative effects on TAM. Exposure–response relationships between the average TAM concentration under actual dosing and key efficacy and safety end points were assessed using data from the 24‐week randomized period of three phase III trials in patients with myelofibrosis ( N = 417). After relevant covariate adjustment, significant positive relationships were identified with spleen volume reduction and transfusion independence (the latter specifically in JAK inhibitor–experienced patients), but not symptom improvement. Greater TAM exposure was significantly associated with lower odds of grade 3/4 anemia and higher odds of any‐grade peripheral neuropathy, although the latter was infrequently observed in phase III trials. There was no significant relationship with grade ≥ 3 thrombocytopenia or any‐grade diarrhea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPyrimidinesBenzamidesPyrrolidinesProtein Kinase InhibitorsJanus Kinase InhibitorsHumansMaleFemaleMiddle AgedModels, BiologicalAgedAdultJanus Kinase 1Clinical Trials, Phase II as TopicClinical Trials, Phase III as TopicClinical Trials, Phase I as TopicJanus Kinase 2Bridged-Ring Compounds

Substanzen

PyrimidinesBenzamidesPyrrolidinesN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideJanus Kinase 1Protein Kinase InhibitorsJanus Kinase Inhibitors11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…Janus Kinase 2Bridged-Ring Compounds

Autor:innen und Institutionen

  • InnoMx, Outremont, Quebec, Canada.
  • GSK, Waltham, Massachusetts, USA.
  • GSK, Collegeville, Pennsylvania, USA.

ORCID-Profile: Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A G Visser, Geraldine Ferron-Brady, Georgios Vlasakakis

Zitieren

APA

Rich, B., Srinivasan, M., Ho, Y. L., Visser, S. A. G., Ferron-Brady, G., & Vlasakakis, G. (2026). Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. Clinical Pharmacology & Therapeutics, 119(3), 629-640. https://doi.org/10.1002/cpt.70076

Vancouver

Rich B, Srinivasan M, Ho YL, Visser SAG, Ferron-Brady G, Vlasakakis G. Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. Clinical Pharmacology & Therapeutics. 2026;119(3):629-640. doi:10.1002/cpt.70076

BibTeX
@article{Rich2026,
  author = {Rich, Benjamin and Srinivasan, Meenakshi and Ho, Yu Liu and Visser, Sandra A G and Ferron-Brady, Geraldine and Vlasakakis, Georgios},
  title = {Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {3},
  pages = {629--640},
  doi = {10.1002/cpt.70076}
}
Kostenlos starten →